ATNF | 180 Life Sciences Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.1001 - 2.3348
52 Week Range	1.1600 - 17.75
Beta	1.40
Implied Volatility	592.65%
IV Rank	N/A
Day's Volume	66,650
Average Volume	1,992,820
Shares Outstanding	1,976,999
Market Cap	4,448,248
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-06-27

Valuation
Profitability
Growth
Health
P/E Ratio	0.28
Forward P/E Ratio	N/A
EPS	7.98
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	ATNF

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

ATNF's peers: ZURA, PHIO, SONN, CDIO, CYTO, IMMX, ENVB, PALI, CNSP, EFTR, NAVB, ZVSA, APGN, DRMA, ENSC, GOVX, HOTH, INM, JAGX, NRBO, QLGN, SMMT, XBIO, ATNFW

*Chart delayed

Analyzing fundamentals for ATNF we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see ATNF Fundamentals page.

Watching at ATNF technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ATNF Technicals page.